

## QUICK FACTS – Biomea Overview

### *Our Company*

We are a clinical-stage biopharmaceutical company focused on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule drug is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. Leveraging our extensive expertise in covalent binding chemistry and development, we built our proprietary FUSION™ System discovery platform to advance a pipeline of novel covalent small molecule product candidates.

Our lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective covalent inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. In preclinical studies, administration of BMF-219 has resulted in robust anti-tumor responses across a range of liquid and solid tumor models and has been generally well-tolerated in animal studies. Additionally, administration of BMF-219 produced a pronounced effect in preclinical models of diabetes, normalizing glucose levels during treatment and even after drug washout. As of December 31, 2022, BMF-219 is being evaluated in up to 8 liquid and solid tumor types and in type 2 diabetes, across 3 ongoing clinical trials.

Beyond BMF-219, we are utilizing our novel FUSION™ System to pioneer covalent treatments against other high-value genetic drivers of disease. In May 2022, we announced our second development candidate, BMF-500, a covalent inhibitor of FLT3. We expect to file an IND to study BMF-500 in acute leukemias in the first half of 2023.

We are currently advancing additional preclinical covalent small molecule programs for the treatment of select cancers and expect to nominate our third development candidate in the first half of 2023. Our goal is to utilize our capabilities and platform to become a leader in developing covalent small molecules to maximize the depth and durability of clinical benefit when treating various cancers.

### *Our Management Team*

After working closely together at Pharmacyclics, our Chief Executive Officer and Chairman of the Board of Directors, Thomas Butler, and Chief Operating Officer and President, Ramses Erdtmann, founded Biomea Fusion in 2017 with the goal of developing targeted therapies for patients suffering from genetically defined cancers. Our management team has significant experience in precision oncology and in progressing products from early-stage research to clinical trials and ultimately to regulatory approval and commercialization. Together, they bring in-house expertise in medicinal chemistry, biology, translational medicine, computational biology, and chemistry, *in vitro* and *in vivo* pharmacology, biomarker development, and manufacturing. We have also established internal expertise in clinical development, clinical operations, pharmacovigilance, clinical pharmacology, regulatory, and quality. Our team is comprised of former colleagues from Celera, Pharmacyclics, Gilead, and Genentech, including the co-inventors of covalent inhibitors Imbruvica, Remdesivir, and Harvoni. We are supported by our board of directors, scientific advisory board, and a leading syndicate of investors.